Biologic and pharmacologic therapies in clinical development for the inflammatory response in COPD

Drug Discovery Today

Volumn 15, Issue 9-10, 2010, Pages 396-405

  Morjaria, Jaymin B ^a   Malerba, Mario ^b   Polosa, Riccardo ^c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF BRESCIA   (Italy)

^c Direttore UOC di Medicina Interna   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABN 912; ABX IL 8; AZD 1236; AZD 3342; AZD 4818; AZD 9668; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CANAKINUMAB; CHEMOKINE RECEPTOR ANTAGONIST; CORTICOSTEROID; CXCL1 CHEMOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GW 856553; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOCYTE ELASTASE INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; MUSCARINIC RECEPTOR BLOCKING AGENT; ONO 6818; PLACEBO; SB 681323; SCH 527123; THEOPHYLLINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AIRWAY REMODELING; ASTHMA; BRONCHODILATATION; BRONCHUS HYPERREACTIVITY; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LOADING DRUG DOSE; LUNG EMPHYSEMA; NEUTROPHIL CHEMOTAXIS; NEUTROPHILIC ASTHMA; NONHUMAN; PATHOGENESIS; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHEMOKINES; CLINICAL TRIALS AS TOPIC; CYTOKINES; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; HUMANS; IMMUNITY, CELLULAR; INFLAMMATION; MODELS, IMMUNOLOGICAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 77952548792     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.03.001     Document Type: Review

References (126)

1. Pauwels R.A., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am. J. Respir. Crit. Care Med. 2001, 163:1256-1276.
2. MacNee W. Pathogenesis of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2005, 2:258-266.
3. Salvi S.S., Barnes P.J. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009, 374:733-743.
4. Barnes P.J., et al. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur. Respir. J. 2003, 22:672-688.
5. Pauwels R.A., et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. 1999, 340:1948-1953.
6. Culpitt S.V., et al. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999, 160:1635-1639.
7. Hogg J.C., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004, 350:2645-2653.
8. Kumar R., et al. Acute and Chronic Inflammation 2005, Elsevier Saunders.
9. Grashoff W.F., et al. Chronic obstructive pulmonary disease: role of bronchiolar mast cells and macrophages. Am. J. Pathol. 1997, 151:1785-1790.
10. Knowles M.R., Boucher R.C. Mucus clearance as a primary innate defense mechanism for mammalian airways. J. Clin. Invest. 2002, 109:571-577.
11. Keatings V.M., et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. J. Respir. Crit. Care Med. 1996, 153:530-534.
12. Peleman R.A., et al. The cellular composition of induced sputum in chronic obstructive pulmonary disease. Eur. Respir. J. 1999, 13:839-843.
13. Vandivier R.W., et al. Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest 2006, 129:1673-1682.
14. Johann A.M., et al. Recognition of apoptotic cells by macrophages activates the peroxisome proliferator-activated receptor-gamma and attenuates the oxidative burst. Cell Death Differ. 2006, 13(9):1533-1540.
15. Patel V.A., et al. Apoptotic cells, at all stages of the death process, trigger characteristic signaling events that are divergent from and dominant over those triggered by necrotic cells: implications for the delayed clearance model of autoimmunity. J. Biol. Chem. 2006, 281:4663-4670.
16. Traves S.L., et al. Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD. Thorax 2002, 57:590-595.
17. Gomez-Cambronero J., et al. Granulocyte-macrophage colony-stimulating factor is a chemoattractant cytokine for human neutrophils: involvement of the ribosomal p70 S6 kinase signaling pathway. J. Immunol. 2003, 171:6846-6855.
18. Tanino M., et al. Increased levels of interleukin-8 in BAL fluid from smokers susceptible to pulmonary emphysema. Thorax 2002, 57:405-411.
19. Stockley R.A. Neutrophils and protease/antiprotease imbalance. Am. J. Respir. Crit. Care Med. 1999, 160:S49-S52.
20. Stanescu D., et al. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996, 51:267-271.
21. Vernooy J.H., et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am. J. Respir. Crit. Care Med. 2002, 166:1218-1224.
22. Kikly K., et al. The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr. Opin. Immunol. 2006, 18:670-675.
23. Molet S., et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J. Allergy Clin. Immunol. 2001, 108:430-438.
24. Chen Y., et al. Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop. J. Biol. Chem. 2003, 278:17036-17043.
25. Jones C.E., Chan K. Interleukin-17 stimulates the expression of interleukin-8, growth-related oncogene-alpha, and granulocyte-colony-stimulating factor by human airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 2002, 26:748-753.
26. Vanaudenaerde B.M., et al. Interleukin-17 stimulates release of interleukin-8 by human airway smooth muscle cells in vitro: a potential role for interleukin-17 and airway smooth muscle cells in bronchiolitis obliterans syndrome. J. Heart Lung Transplant 2003, 22:1280-1283.
27. Langrish C.L., et al. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol. Rev. 2004, 202:96-105.
28. Aggarwal S., et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 2003, 278:1910-1914.
29. Kim V., et al. New concepts in the pathobiology of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2008, 5:478-485.
30. Mio T., et al. Cigarette smoke induces interleukin-8 release from human bronchial epithelial cells. Am. J. Respir. Crit. Care Med. 1997, 155:1770-1776.
31. Sakao S., et al. Association of tumor necrosis factor alpha gene promoter polymorphism with the presence of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001, 163:420-422.
32. Cromwell O., et al. Expression and generation of interleukin-8 IL-6 and granulocyte-macrophage colony-stimulating factor by bronchial epithelial cells and enhancement by IL-1β and tumour necrosis factor-alpha. Immunology 1992, 77:330-337.
33. von Asmuth E.J., et al. IL-6 IL-8 and TNF production by cytokine and lipopolysaccharide-stimulated human renal cortical epithelial cells in vitro. Eur. Cytokine Netw. 1994, 5:301-310.
34. Standiford T.J., et al. Alveolar macrophage-derived cytokines induce monocyte chemoattractant protein-1 expression from human pulmonary type II-like epithelial cells. J. Biol. Chem. 1991, 266:9912-9918.
35. Di Stefano A., et al. Upregulation of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis. Am. J. Respir. Crit. Care Med. 1994, 149:803-810.
36. Mulligan M.S., et al. Neutrophil-dependent acute lung injury. Requirement for P-selectin (GMP-140). J. Clin. Invest. 1992, 90:1600-1607.
37. Takeyama K., et al. Activation of epidermal growth factor receptors is responsible for mucin synthesis induced by cigarette smoke. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 280:L165-L172.
38. Kampf C., et al. Effects of TNF-α. IFN-γ and IL-beta on normal human bronchial epithelial cells. Eur. Respir. J. 1999, 14:84-91.
39. Miyazaki Y., et al. Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J. Clin. Invest. 1995, 96:250-259.
40. Wu A.J., et al. Interferon-γ induced cell death in a cultured human salivary gland cell line. J. Cell. Physiol. 1996, 167:297-304.
41. Vernooy J.H., et al. Increased granzyme A expression in type II pneumocytes of patients with severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2007, 175:464-472.
42. Takabatake N., et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000, 161:1179-1184.
43. Garrod R., et al. The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (COPD). Prim. Care Respir. J. 2007, 16:236-240.
44. de Godoy I., et al. Elevated TNF-α production by peripheral blood monocytes of weight-losing COPD patients. Am. J. Respir. Crit. Care Med. 1996, 153:633-637.
45. Park J.Y., Pillinger M.H. Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull. NYU Hosp. Jt. Dis. 2007, 65(Suppl. 1):S4-S10.
46. Muraguchi A., et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J. Exp. Med. 1988, 167:332-344.
47. Man S.F., et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006, 61:849-853.
48. Soler N., et al. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur. Respir. J. 1999, 14:1015-1022.
49. Wedzicha J.A., et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb. Haemost. 2000, 84:210-215.
50. Bucchioni E., et al. High levels of interleukin-6 in the exhaled breath condensate of patients with COPD. Respir. Med. 2003, 97:1299-1302.
51. Newbold P., et al. Evidence to support a role for IL-1β in the COPD disease process. Proc. Am. Thorac. Soc. 2005, 2:A395.
52. Lappalainen U., et al. Interleukin-1beta causes pulmonary inflammation, emphysema, and airway remodeling in the adult murine lung. Am. J. Respir. Cell Mol. Biol. 2005, 32:311-318.
53. Lacraz S., et al. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J. Clin. Invest. 1995, 96:2304-2310.
54. Barcelo B., et al. Intracellular cytokine profile of T lymphocytes in patients with chronic obstructive pulmonary disease. Clin. Exp. Immunol. 2006, 145:474-479.
55. Vlahos R., et al. Differential protease, innate immunity, and NF-κB induction profiles during lung inflammation induced by subchronic cigarette smoke exposure in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006, 290:L931-L945.
56. Hamilton J.A., Anderson G.P. GM-CSF biology. Growth Factors 2004, 22:225-231.
57. Xing Z., et al. Transfer of granulocyte-macrophage colony-stimulating factor gene to rat lung induces eosinophilia, monocytosis, and fibrotic reactions. J. Clin. Invest. 1996, 97:1102-1110.
58. Stampfli M.R., et al. GM-CSF transgene expression in the airway allows aerosolized ovalbumin to induce allergic sensitization in mice. J. Clin. Invest. 1998, 102:1704-1714.
59. Shibata Y., et al. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity 2001, 15:557-567.
60. Balbi B., et al. Increased bronchoalveolar granulocytes and granulocyte/macrophage colony-stimulating factor during exacerbations of chronic bronchitis. Eur. Respir. J. 1997, 10:846-850.
61. Vlahos R., et al. Therapeutic potential of treating chronic obstructive pulmonary disease (COPD) by neutralising granulocyte macrophage-colony stimulating factor (GM-CSF). Pharmacol. Ther. 2006, 112:106-115.
62. Ito K., et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl. J. Med. 2005, 352:1967-1976.
63. Strieter R.M., et al. Interleukin-8. A corneal factor that induces neovascularization. Am. J. Pathol. 1992, 141:1279-1284.
64. Arenberg D.A., et al. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J. Clin. Invest. 1996, 97:2792-2802.
65. Boring L., et al. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J. Clin. Invest. 1997, 100:2552-2561.
66. Kurihara T., et al. Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J. Exp. Med. 1997, 186:1757-1762.
67. Lu B., et al. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J. Exp. Med. 1998, 187:601-608.
68. Mack M., et al. Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J. Immunol. 2001, 166:4697-4704.
69. 3H]5HT release. Immunology 1995, 86:434-440.
70. Taub D.D., et al. Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J. Clin. Invest. 1995, 95:1370-1376.
71. Schweickart V.L., et al. CCR11 is a functional receptor for the monocyte chemoattractant protein family of chemokines. J. Biol. Chem. 2001, 276:856.
72. de Boer W.I., et al. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J. Pathol. 2000, 190:619-626.
73. Rolfe M.W., et al. Expression and regulation of human pulmonary fibroblast-derived monocyte chemotactic peptide-1. Am. J. Physiol. 1992, 263:L536-L545.
74. Warhurst A.C., et al. Interferon γ induces differential upregulation of alpha and beta chemokine secretion in colonic epithelial cell lines. Gut 1998, 42:208-213.
75. Penton-Rol G., et al. Selective inhibition of expression of the chemokine receptor CCR2 in human monocytes by IFN-γ. J. Immunol. 1998, 160:3869-3873.
76. Gunn M.D., et al. Monocyte chemoattractant protein-1 is sufficient for the chemotaxis of monocytes and lymphocytes in transgenic mice but requires an additional stimulus for inflammatory activation. J. Immunol. 1997, 158:376-383.
77. Gonzalo J.A., et al. The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J. Exp. Med. 1998, 188:157-167.
78. Hautamaki R.D., et al. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997, 277:2002-2004.
79. Weber K.S., et al. Expression of CCR2 by endothelial cells: implications for MCP-1 mediated wound injury repair and in vivo inflammatory activation of endothelium. Arterioscler. Thromb. Vasc. Biol. 1999, 19:2085-2093.
80. Salcedo R., et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000, 96:34-40.
81. Furukawa Y., et al. Anti-monocyte chemoattractant protein-1/monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ. Res. 1999, 84:306-314.
82. Gharaee-Kermani M., et al. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J. Biol. Chem. 1996, 271:17779-17784.
83. Jiang Y., et al. Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J. Immunol. 1992, 148:2423-2428.
84. Gong J.H., Clark-Lewis I. Antagonists of monocyte chemoattractant protein 1 identified by modification of functionally critical NH2-terminal residues. J. Exp. Med. 1995, 181:631-640.
85. Mirzadegan T., et al. Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle. J. Biol. Chem. 2000, 275:25562-25571.
86. Rodriguez-Frade J.M., et al. The chemokine monocyte chemoattractant protein-1 induces functional responses through dimerization of its receptor CCR2. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:3628-3633.
87. van Noord J.A., et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur. Respir. J. 2005, 26:214-222.
88. Barnes N.C., et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 2006, 173:736-743.
89. Bourbeau J., et al. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007, 62:938-943.
90. Chung K.F., et al. Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future. Eur. J. Clin. Pharmacol. 2009, 65:853-871.
91. Cosio B.G., et al. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J. Exp. Med. 2004, 200:689-695.
92. Ito K., et al. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:8921-8926.
93. van der Vaart H., et al. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005, 172:465-469.
94. Dentener M.A., et al. Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: a pilot study. Respiration 2008.
95. Rennard S.I., et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2007, 175:926-934.
96. Bongartz T., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. J. Am. Med. Assoc. 2006, 295:2275-2285.
97. Mahler D.A., et al. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 2004, 126:926-934.
98. Castro P., et al. Inhibition of interleukin-1beta reduces mouse lung inflammation induced by exposure to cigarette smoke. Eur. J. Pharmacol. 2004, 498:279-286.
99. Churg A., et al. The role of interleukin-1β in murine cigarette smoke-induced emphysema and small airway remodeling. Am. J. Respir. Cell Mol. Biol. 2009, 40(4):482-490.
100. Safety and efficacy of multiple doses of ACZ885 in chronic obstructive pulmonary disease (COPD) patients. (). http://www.clinicaltrial.gov/ct2/show/NCT00581945%3Fterm=COPD+AND+ACZ%26rank=1.
101. Tolerability/safety and efficacy on inhaled AZD4818 in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (TOP). http://www.clinicaltrial.gov/ct2/show/NCT00629239%3Fterm=AZD-4818%26rank=2.
102. Norman P. AZD-4818, a chemokine CCR1 antagonist: WO2008103126 and WO2009011653. Expert Opin. Ther. Pat. 2009, 19:1629-1633.
103. Study of the effects of SCH 527123 in subjects with moderate to severe chronic obstructive disease (COPD) (Protocol No. P05575). http://www.clinicaltrial.gov/ct2/show/NCT01006616%3Fterm=sch-527123%26rank=6.
104. Neutrophilic asthma study with SCH 527123 (Study P05365AM2). http://www.clinicaltrial.gov/ct2/show/NCT00632502%3Fterm=sch-527123%26rank=5.
105. Efficacy and safety of twice daily 60mg AZD9668 in COPD for 12 weeks in patients on background budesonide/formoterol. http://www.clinicaltrial.gov/ct2/show/NCT01023516%3Fterm=AZD-9668+COPD%26rank=3.
106. Safety/tolerability study with AZD1236 in chronic obstructive pulmonary disease (COPD) patients (CERA). http://www.clinicaltrial.gov/ct2/show/NCT00758459%3Fterm=AZD1236+copd%26rank=1.
107. A phase IIa study assessing the effects of AZD1236 on biomarkers in chronic obstructive pulmonary disease (COPD) patients (BICO). http://www.clinicaltrial.gov/ct2/show/NCT00758706%3Fterm=AZD1236+copd%26rank=2.
108. Norman P. Selective MMP-12 inhibitors: WO-2008057254. Expert Opin. Ther. Pat. 2009, 19:1029-1034.
109. Li W., et al. A selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary disease (COPD): discovery of (S)-2-(8-(methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408). J. Med. Chem. 2009, 52:1799-1802.
110. Medicherla S., et al. p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation. J. Pharmacol. Exp. Ther. 2008, 324:921-929.
111. Bhavsar P.K., et al. Reversal of relative corticosteroid insensitivity in PBMCs from patients with COPD by p38 MAPK inhibition. Am. J. Respir. Crit. Care Med. 2009, 179:A6187.
112. Safety and anti-inflammatory effect of SB681323 in patients with chronic obstructive pulmonary disease (COPD). http://www.clinicaltrial.gov/ct2/show/NCT00144859%3Fterm=681323+COPD%26rank=2.
113. Singh D., et al. A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. J. Clin. Pharmacol. 2010, 50:94-100.
114. Bourbeau J., Johnson M. New and controversial therapies for chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2009, 6:553-554.
115. A 12 week study to assess efficacy and safety of GW856553 in subjects with chronic obstructive pulmonary disease (COPD). http://www.clinicaltrial.gov/ct2/show/NCT00642148%3Fterm=856553+COPD%26rank=1.
116. A study to investigate the effects of GW856553 on patients with COPD (chronic obstructive pulmonary disease). http://www.clinicaltrial.gov/ct2/show/NCT00392587%3Fterm=856553+COPD%26rank=2.
117. Marwick J.A., et al. Inhibition of PI3Kdelta restores glucocorticoid function in smoking-induced airway inflammation in mice. Am. J. Respir. Crit. Care Med. 2009, 179:542-548.
118. Birrell M.A., et al. IkappaB kinase-2-independent and -dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic. Mol. Pharmacol. 2006, 69:1791-1800.
119. Tudhope S.J., et al. The role of IkappaB kinase 2, but not activation of NF-κB, in the release of CXCR3 ligands from IFN-γ-stimulated human bronchial epithelial cells. J. Immunol. 2007, 179:6237-6245.
120. Bamborough P., et al. Progress towards the development of anti-inflammatory inhibitors of IKKbeta. Curr. Top. Med. Chem. 2009, 9:623-639.
121. Roth M.D., et al. Feasibility of retinoids for the treatment of emphysema study. Chest 2006, 130:1334-1345.
122. Repair Tier 2 - (retinoids in emphysema patients on the Alpha-1-Antitrypsin International Registry) (Protocol No NA17598). http://www.roche-trials.com/patient/trials/trial102.html.
123. TESRA (treatment of emphysema with a gamma-selective retinoid agonist). http://www.clinicaltrial.gov/ct2/show/NCT00413205%3Fterm=emphysema+AND+retinoid%26rank=2.
124. Kvale P., et al. Design of two studies in emphysema with an orally active, gamma selective retinoid agonist (R667). Chest 2007, 132:481.
125. A study to evaluate the safety and tolerability of SB-656933-AAA following repeated doses in healthy adult subjects. http://www.clinicaltrial.gov/ct2/show/NCT00504439%3Fterm=CXCR+copd%26rank=1.
126. A phase II study to evaluate the efficacy and safety of ph-797804 in adults with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrial.gov/ct2/show/NCT00559910%3Fterm=797804+copd%26rank=1.